Alnylam Pharmaceuticals (ALNY) Equity Average (2010 - 2026)

Alnylam Pharmaceuticals has reported Equity Average for 17 years, with the latest figure at $932.3 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 278.03% year-over-year to $932.3 million; the trailing twelve-month figure through Mar 2026 stood at $932.3 million (up 278.03% YoY), and the FY2025 full-year result was $428.1 million, up 657.62% from the prior year.
• Equity Average for Q1 2026 stood at $932.3 million, up from $511.5 million in the prior quarter.
• The five-year high for Equity Average was $932.3 million in Q1 2026, with the low at -$333.7 million in Q2 2023.
• Historically, Equity Average has averaged $100.4 million across 5 years, with a median of $49.7 million in 2024.
• Annual changes were most pronounced in 2023 — Equity Average plunged 629.51% — and 2025, when it surged 1554.27%.
• Alnylam Pharmaceuticals' Equity Average stood at -$112.9 million in 2022, then sank by 71.13% to -$193.3 million in 2023, then soared by 125.73% to $49.7 million in 2024, then soared by 928.81% to $511.5 million in 2025, then soared by 82.25% to $932.3 million in 2026.
• The last three Equity Average figures came in at $932.3 million (Q1 2026), $511.5 million (Q4 2025), and $242.2 million (Q3 2025), per Business Quant data.